Literature DB >> 15683876

Immunochemical and biochemical comparisons of equine monovalent and polyvalent snake antivenoms.

Rutai Raweerith1, Kavi Ratanabanangkoon.   

Abstract

Although the merit of polyvalent antivenoms is well-recognized, there is still doubt in some medical circles as to the relative efficacy and the propensity to cause adverse reactions of polyvalent (pAV) as compared to monovalent (mAV) antivenoms. Immunochemical and biochemical comparisons of equine polyvalent and monovalent antivenoms prepared under the same immunization protocols were therefore made. These antivenoms were prepared against Naja kaouthia (NK), Ophiophagus hannah (OH) and Bungarus fasciatus (BF) venoms. SDS-PAGE analysis of both types of antivenoms showed similar serum protein profiles. The total amount of immunoglobulin (IgG(T)+IgG) in pAVs was slightly but significantly higher than that of mAVs, while the total serum protein content in mAVs was slightly but significantly higher than that of pAVs. The amounts of total hyperimmune IgG(T), determined by ELISA, were similar in mAVs and pAVs. pAVs contained specific antibodies against the principal NK postsynaptic toxin (NK 3) to the same extent as that observed with the anti-N. kaouthia mAV. The antibodies against OH and BF principal postsynaptic toxins (OH II and BF IX) in pAVs were significantly higher than those of the corresponding anti-O. hannah and anti-B. fasciatus mAVs. These results were in concordance with the comparable in vivo neutralization activities of mAVs and pAV previously reported. The apparent dissociation constant (Kd) of anti-OH II antibody in pAVs was comparable to that of the anti-O. hannah mAVs. The apparent K(d)s of anti-NK 3 and anti-BF IX antibodies in the corresponding mAVs were slightly lower than those in pAVs. The Kd values were all in nM range and were considered to be high affinity binding. It is concluded that pAVs could be prepared with potency and protein contents and thus the propensity to cause adverse reaction that were comparable to those of mAVs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15683876     DOI: 10.1016/j.toxicon.2004.10.019

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  6 in total

1.  Virtual screening against alpha-cobratoxin.

Authors:  Maleeruk Utsintong; Todd T Talley; Palmer W Taylor; Arthur J Olson; Opa Vajragupta
Journal:  J Biomol Screen       Date:  2009-09-04

2.  Cross neutralization of Afro-Asian cobra and Asian krait venoms by a Thai polyvalent snake antivenom (Neuro Polyvalent Snake Antivenom).

Authors:  Poh Kuan Leong; Si Mui Sim; Shin Yee Fung; Khomvilai Sumana; Visith Sitprija; Nget Hong Tan
Journal:  PLoS Negl Trop Dis       Date:  2012-06-05

3.  Effective equine immunization protocol for production of potent poly-specific antisera against Calloselasma rhodostoma, Cryptelytrops albolabris and Daboia siamensis.

Authors:  Sompong Sapsutthipas; Poh Kuan Leong; Surasak Akesowan; Ronachai Pratanaphon; Nget Hong Tan; Kavi Ratanabanangkoon
Journal:  PLoS Negl Trop Dis       Date:  2015-03-16

4.  A pan-specific antiserum produced by a novel immunization strategy shows a high spectrum of neutralization against neurotoxic snake venoms.

Authors:  Kavi Ratanabanangkoon; Kae Yi Tan; Kritsada Pruksaphon; Chaiya Klinpayom; José María Gutiérrez; Naeem H Quraishi; Choo Hock Tan
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

5.  The development and evaluation of the efficacy of ovine-derived experimental antivenom immunoserum against Macrovipera lebetina obtusa (MLO) venom.

Authors:  Arsen Kishmiryan; Gevorg Ghukasyan; Lusine Ghulikyan; Anna Darbinyan; Lilia Parseghyan; Armen Voskanyan; Naira M Ayvazyan
Journal:  J Venom Res       Date:  2021-02-17

6.  Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.

Authors:  Nessrin Alomran; Jaffer Alsolaiss; Laura-Oana Albulescu; Edouard Crittenden; Robert A Harrison; Stuart Ainsworth; Nicholas R Casewell
Journal:  PLoS Negl Trop Dis       Date:  2021-08-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.